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Abstract
Despite the availability of safe and effective hepatitis B virus (HBV) vaccines for more than 30 years, the burden of hepatitis B disease is still
substantial. In 1992, the WHO recommended the inclusion of HBV vaccination in all national vaccination programmes. As of 2012, 47 of the
53 European countries (89%) had implemented a universal hepatitis B vaccination programme. The most recent countries to follow the
recommendation were Ireland (in 2008) and the Netherlands (in 2011). Still, six countries (Denmark, Finland, Iceland, Norway, Sweden and
the UK) adopt risk-group-targeted vaccination only, instead of adding a universal vaccination programme. However, changing demography,
increasing immigration and the current vaccine costs make the cost–beneﬁt ratios in these remaining low endemicity countries strongly in
favour of universal HBV vaccination. Global efforts, including a cohesive European vaccination policy, are essential to control and prevent
hepatitis B.
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Hepatitis B is a prime target for prevention (and theoretically
eradication) through vaccination, because it represents a
serious public health threat, humans are the only known
reservoir and safe and effective vaccines have been available
for >30 years.
Still, the global burden of hepatitis B disease is substantial.
About 2000 million people have been infected with hepatitis B
virus (HBV) worldwide, 240 million people are chronically
infected and between 500 000 and 700 000 people die
annually as a result of HBV infection or its complications,
such as liver cirrhosis and hepatocellular carcinoma [1]. In the
European region of the WHO, the number of chronic carriers
is estimated at 13 million, affecting 1 out of 50 people [2]. The
highest hepatitis B surface antigen (HBsAg) prevalence rates in
the general population are registered in Uzbekistan (13%) [2].
Although quality and standardized viral hepatitis surveillance
data for Europe are still scarce, enhanced surveillance of
hepatitis B across the countries in the European Economic
Area during the past decade has highlighted the signiﬁcant
burden of the infection [3]. In 2011, over 17 000 newly
identiﬁed cases of hepatitis B were reported from 28 European
Economic Area countries.
Hepatitis B vaccine provides long-term protection
(>20 years) against the infection and its consequences [4].
For population immunization, two strategies are used:
universal vaccination and high-risk group targeting.
A variety of schedules may be used for universal hepatitis B
immunization and different age groups can be targeted, depend-
ing on the local epidemiological situation and logistic consider-
ations. Universal newborn or infant vaccination aims to address
the people who would otherwise be infected perinatally or in
early childhood,when the risk of chronic infection is highest: 90%
of infants of HBsAg and hepatitis B e antigen (HBeAg)-positive
mothers, infected during the ﬁrst year of life, develop
chronic infection, compared with 30% of children infected
between 1 and 4 years of age and <5% of infected adults [5].
In countries with high endemicity, administration of the ﬁrst
dose of HBV vaccine as soon as possible (<24 h) after birth is a
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critical step in preventing perinatal HBV transmission. The risk
of HBV infection among infants born to HBsAg-positive
mothers was found to be eight times higher when the birth
dose was administered after 7 days from birth, compared with
when it was administered within the ﬁrst 3 days after birth [6].
In countries where mothers deliver in a healthcare setting, a
high ﬁrst-dose HBV vaccine coverage can be achieved when
the vaccine is administered at birth, with the potential of
increased compliance for subsequent doses. Indeed, studies in
the USA indicate that children who received the ﬁrst dose of
hepatitis B vaccine during their ﬁrst month of life (usually the
birth dose) are more likely to complete the hepatitis B vaccine
series as well as other immunizations [7,8]. A birth dose of
hepatitis B vaccination for all newborns also provides a safety
net against gaps in maternal hepatitis B screening programmes
and errors in reporting [8].
However, the delivery of a birth dose places special
demands on health systems to respond within 24 h of
childbirth, and attitudes and practices of families and health-
care providers at the time of birth are often different to those
relating to older infants [6]. Administering the ﬁrst dose of
HBV vaccine using combination vaccines at a later age (infant
vaccination), can take advantage of the existing childhood
immunization programmes, without requiring additional visits
or injections and is therefore an economically attractive and
effective way of achieving universal vaccination with high
coverage [9].
In countries with low endemicity, where hepatitis B
infection is mainly acquired through risk behaviour by young
adults, universal vaccination programmes (newborn/infant and/
or adolescents) aim to protect the entire population before
they reach the age of greatest incidence of infection (adoles-
cence and early adulthood). But in some low-prevalence
countries, targeted risk-group vaccination is used as an
alternative to universal immunization. Yet, high-risk pro-
grammes have several shortcomings and have so far failed to
control viral hepatitis infection in the general population. The
strategy requires all individuals in a high-risk group to have
access to healthcare, be identiﬁed, and get vaccinated before
they are infected. This is labour and cost intensive, at-risk
groups are often hard to reach and the reported vaccine
coverage achieved in the target populations has been too low
to impact on the transmission of infection [10–13]. Further-
more, in industrialized countries, about one-third of HBV
infections occur in people with no known risk factor and are
therefore missed by a high-risk approach [14]. Finally, targeting
speciﬁc groups only wrongly suggests that hepatitis B is not a
concern for the rest of the population [15].
In 1992, the WHO recommended the inclusion of HBV
vaccination in all national vaccination programmes. All infants
should receive their ﬁrst dose of hepatitis B vaccine as soon as
possible after birth, preferably within 24 h [16]. As of 2012,
hepatitis B vaccine was introduced in 181 countries (93%),
reaching a global coverage with three doses of 79% compared
with a coverage of 30% in 2000 [17,18].
Out of the 53 Member States of the European WHO
Region, 47 (89%) introduced universal vaccination (Table 1).
A coverage of 90% or more for three doses of hepatitis B
vaccine is achieved in most countries, with lower coverage
rates registered in Ukraine (21%) and France (51%) (Table 1)
[19]. In 2012, 29 European countries targeted newborn
babies, 15 targeted infants and three targeted older children
or adolescents (Hungary, Slovenia and Switzerland). Some
countries combine immunization of different age groups, at a
national level, or in areas of high endemicity only (e.g. Russian
Federation, Kazakhstan) (Table 2) [20–24]. The data on the
age groups covered by vaccination presented in Table 2 may
underestimate the reality, because populations targeted by
regional strategies or catch-up campaigns are not included.
Indeed, catch-up programmes for older age groups have been
or are still conducted in many countries [23,24]. On the
other hand, the age cohorts targeted by routine programmes
might be incompletely vaccinated, because vaccination cover-
age varied over time, with low coverage rates reported
especially in the ﬁrst years after the introduction of the
vaccine.
The ﬁrst countries to implement universal hepatitis B
vaccination in Europe were Cyprus in 1990, Bulgaria, Italy,
Spain (autonomous region of Catalonia) and San Marino in
1991, and Israel in 1992 (Tables 1 and 2). Further progress was
achieved over the years. The success of these routine
childhood and adolescent immunization programmes in inter-
rupting HBV transmission and the cost-effectiveness of the
strategy, even in low prevalence countries, has been well
demonstrated [25–29].
The most recent European countries to introduce universal
infant HBV vaccination were Ireland (2008) and the Nether-
lands (2011). An economic evaluation in Ireland in 2007
concluded that universal infant HBV vaccination was a
cost-effective intervention compared with a selective vaccina-
tion policy, based on the use of a hexavalent vaccine [30]. As
the disease burden of hepatitis B in the Netherlands did not
decrease over the past 20 years and the targeted approach
failed to reach a signiﬁcant part of the risk groups, the Health
Council of the Netherlands recommended universal infant
immunization in 2010, considering that universal vaccination
means better protection for high-risk groups as well as the
whole population [31]. Still, by 2013, six European countries
have not yet introduced universal immunization against
hepatitis B: Denmark, Finland, Iceland, Norway, Sweden and
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the UK. They adopt risk-group-targeted vaccination, in addi-
tion to screening of pregnant women and immunization of
neonates exposed to infection.
The Danish national guidelines for hepatitis B immunization
were re-evaluated in 2005 to assess the possible need for
universal childhood immunization, and the National Board of
Health concluded that there were insufﬁcient reasons to
change their policy [32]. However, more recent assessments in
the Northern European countries recommend considering
universal infant vaccination because of the lack of effectiveness
of at-risk vaccination in reducing the overall incidence of
hepatitis B [15,33,34] and the cost-effectiveness of universal
infant vaccination [35]. Several working groups in Norway are
currently advocating routine HBV vaccination in their country,
and a programme for routine vaccination of children has
already been in place in at least one county (Norbotten) in
Sweden since 2011 [36].
Indeed, changing demography with increasing immigration
and increased risk for HBV introduction from countries with
intermediate and high endemicity makes the cost–beneﬁt
ratios in the remaining countries where endemicity is low and
where there is no universal vaccination strongly in favour of
universal HBV vaccination, in particular with the current
vaccine costs.
TABLE 1. Implementation of universal hepatitis B immunization programmes and vaccination coverage for three doses of
vaccine in the European Region of the World Health Organization (n = 53), up to 2012
Country
Universal
programme
(national level)
Year
of
introduction
Additional
universal
programme
Year
of
introduction
Infant
coveragea
(2011), %
Albania Newborn 1994 99
Andorra Newborn 1997 99
Armenia Newborn 1999 95
Austria Infant 1997 83
Azerbaijan Newborn 2001 96
Belarus Newborn 1999 Adolescent (13 years) 1998–1999 98
Belgium Infant 1999 Adolescent (12 years) 1999 97
Bosnia and Herzegovina Newborn 2001 88
Bulgaria Newborn 1991 96
Croatia Infant 2007 Adolescent (12–13 years) 1999 97
Cyprus Infant 1990 96
Czech Republic Infant 2001 99
Denmark – –
Estonia Newborn 2003 Adolescent (12–13 years) 1999 94
Finland – –
France Infant 1995 Adolescent (11–13 years) 1994–1995 51
Georgia Newborn 2000 92
Germany Infant 1995 87
Greece Infant 1998 95
Hungary Adolescent (14 y) 1999 –
Iceland – –
Ireland Infant 2008 95
Israel Newborn 1992 99
Italy Infant 1991 Adolescent (12 years) 1991 96
Kazakhstan Newborn 1998 99
Kyrgyzstan Newborn 2001 96
Latvia Infant 1997 91
Lithuania Newborn 1998 Adolescent (12 years) 2002 95
Luxembourg Infant 1996 95
Malta Infant 1997 82
Monaco Infant 1999 99
Montenegro Infant 2004 91
Netherlands Infant 2011 –
Norway – –
Poland Newborn 1996 Adolescent (14 years) 2000 98
Portugal Newborn 2000 Adolescent (10–13 years) 1994–1995 97
Republic of Moldova Newborn 1995 Adolescent (10–14 years) 2005 96
Romania Newborn 1995 Child (9 years)/Adults (18 years) 1999/2004 96
Russian Federation Newborn 2002 97
San Marino Newborn 1991 86
Serbia Newborn 2005 94
Slovakia Infant 1998 Child (10 years) 2004 99
Slovenia Child (5–6 years) 1998 92
Spain Newborn 2003 Adolescent (12 years) 1996 97
Sweden – 29
Switzerland Adolescent (11 years) 1998 –
Tajikistan Newborn 2003 96
The FYR of Macedonia Newborn 2004 96
Turkey Infant 1998 96
Turkmenistan Newborn 2002 97
UK – –
Ukraine Newborn 2000 21
Uzbekistan Newborn 1998 99
aHepB3 vaccination coverage in infants, 2011. Source: WHO. Centralized Information for Infectious Diseases (CISID). Vaccination coverage. Available at http://data.euro.who.int/
cisid/?TabID=319427.
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TABLE 2. Age groups covered by universal hepatitis B immunization programmes in the European Region of theWHO (n = 53),
up to 2012
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Given the high levels of immigration within the EU, the lack
of uniformity in vaccination policies threatens the potential for
EU-wide strategies to contain the spread of HBV [37].
Therefore, an expert group on hepatitis (within the European
Parliament) recommended in 2007 to encourage a cohesive
policy with universal immunization of all newborns/infants and/
or adolescents throughout Europe, as well as effective vacci-
nation of populations at risk, in line with WHO recommenda-
tions [37]. WHO further strongly recommends that all regions
and the associated countries develop time-bound realistic goals
for hepatitis control and deﬁne speciﬁc process indicators,
focusing on coverage of the birth dose and coverage of three
doses of hepatitis B vaccine [16]. TheWHO Regional Ofﬁce for
Europe should take the Western Paciﬁc Region as an example,
where a regional plan to control hepatitis through immuniza-
tion was published in 2007 [38]. Irrespective of universal
vaccination, programmes targeting behavioural high-risk groups
are further needed until all countries have a generation of
adolescents and young adults among whom transmission has
been interrupted. In addition, for prevention through immuni-
zation, early diagnosis and effective treatment should be
implemented, to contribute to reduction of transmission.
Hepatitis B is a global public health problem, needing global
efforts to control and prevent the disease.
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